China NMPA Approves Bio-Thera Solutions BAT1806, A Biosimilar to Actemra
By, Admin1 min read
Share
Bio-Thera Solutions, Ltda commercial-stage biopharmaceutical company, announced that the China National Medical Products Administration (NMPA) has approved BAT1806, a biosimilar of Actemra
Found this useful? Share it with your team.
Newsletter
Stay ahead with Clival insights
Subscribe to get the latest updates, data releases and industry information — straight to your inbox.
